Menu
  • About RedHill
  • Products
  • Partnering
  • Investors
  • News
  • Contact
  • CAREERS
  • Press Releases

     
    Press Releases
      Date Summary View
    Feb 25, 2013
    Following a successful comparative bioavailability trial, the Company met with the FDA to discuss its planned New Drug Application (NDA) filing for RHB-102 Company plans to file the RHB-102 NDA in Q4/2013 RHB-102 is a proprietary, extended release, once-daily oral formulation of ondansetron, a leading drug for the prevention of ...
    PDF
    Feb 19, 2013
    Key Planned Milestones for 2013 Include Commencement of Phase III and Phase II/III Studies With RHB-104 (Crohn's Disease) and RHB-105 (H. pylori), Respectively, and New Drug Application (NDA) Filings With RHB-102 (Oncology Support Antiemetic) and RHB-103 (Acute Migraine) TEL-AVIV, Israel, Feb. 19, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma ...
    PDF
    Feb 19, 2013
    RHB-101 is a proprietary, controlled release, once-daily formulation of carvedilol for the treatment of hypertension, congestive heart failure and left ventricular dysfunction The expected expiration date of the US patent is 2024 TEL-AVIV, Israel, Feb. 19, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (...
    PDF
    Feb 14, 2013
    TEL-AVIV, Israel, Feb. 14, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL), an Israeli biopharmaceutical company focusing primarily on development and acquisition of late clinical-stage, patent-protected, new formulations and combinations of existing drugs, announced that it plans to release its FY 2012 results on Tuesday,...
    PDF
    Jan 7, 2013
    Patient Recruitment in an Initial Phase III Study is Planned to Commence Q2/2013; Multi-Site Initiation Process is Underway; Newly Issued Patent Expires no Earlier Than 2029 Additional Planned and Required Studies, Which Include a Second Phase III Crohn's Disease Trial in Europe and Other Supplementary Studies, Are Under Preparation as Part...
    PDF
    Dec 27, 2012
    Trading on NASDAQ to Commence Today, Thursday, December 27th, 2012 Following Final Approvals From SEC and NASDAQ The Listing Does Not Include Capital Raising as Part of the Registration Process RedHill Biopharma Recently Completed a Private Placement of Approximately $6.5 Million TEL-AVIV, Israel, Dec. 27, 2012 (GLOBE NEWSW...
    PDF
    Dec 10, 2012
    PDF
    Dec 10, 2012
    PDF
    Nov 27, 2012
    PDF
    Nov 27, 2012
    PDF
    Page: FirstPrevious ...
    29
    ... NextLast

    Subscribe to press releases